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Abstract The purpose of this study was to compare
the efficacy of intravitreal aflibercept versus
ranibizumab for treating therapy-resistant diabetic
macular oedema (DME). A 69-year-old man presented
with persistent bilateral DME despite previous
ranibizumab treatment. Bilateral study treatment
comprised one cycle of three monthly ranibizumab
injections (0.5 mg), followed by one cycle of three
aflibercept injections (2.0 mg), a second ranibizumab
cycle and a second aflibercept cycle. Baseline visual
acuity (ETDRS score) was 60 letters for the right eye
and 65 letters for the left eye. Baseline central foveal
thickness (CFT) was 305 lm for the right eye and
453 lm for the left eye. Substantially improved
outcomes were observed during the first aflibercept
cycle. CFT was reduced by 150 lm (mean) in both the
eyes and decreased below the lowest level achieved
during the previous 2.5-year ranibizumab treatment.
Visual acuity was improved by 17.5 letters (mean) in
both the eyes. Reintroduction of ranibizumab imme-
diately worsened the status of both eyes back to the
baseline level. During the final aflibercept cycle,
visual acuity and CFT improved to the same levels
achieved during the first aflibercept cycle. In this case
study, we prospectively switched the treatment three
times and observed a dramatic and consistent treat-
ment advantage for aflibercept.
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Introduction
Both ranibizumab and aflibercept are indicated for
treating DME (Food and Drug Administration ap-
proval in 2012 and 2014, respectively) based on the
results of phase III data of RISE/RIDE (ranibizumab)
and VISTA/VIVID (aflibercept) studies [1, 2].
However, no comparative data are available on the
potential differences in the efficacy of ranibizumab
and aflibercept for treating persistent or recurrent
DME. Given the complex aetiopathogenesis of DME
and given the differences in mode of action between
the two drugs, clinical efficacy might be different. We
report here the results of a case study of persistent
bilateral DME, in which intravitreal treatment has
been switched back and forth between ranibizumab
and aflibercept several times. To the best of our
knowledge, this is the first case study to analyse the
effect of switching between the two drugs for treating
DME.
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This study included a 69-year-old man with type I
diabetes who was diagnosed with bilateral DME in
2009. Since February 2011, the patient received
intravitreal anti-VEGF treatment (ranibizumab) for
both the eyes. Despite 2.5 years of near-monthly
ranibizumab treatment (21 injections in both the eyes;
average interval, 38 days), intraretinal and subretinal
fluid persisted. The patient entered the study in May
2013 (baseline). Baseline values were determined
after a one-month washout period from the prestudy
treatment (Online Resource 1). The patient did not
show any signs of other ophthalmological pathologies
besides nonproliferative diabetic retinopathy and
DME (Online Resource 2).
Study design and protocol
This prospective case study compared the efficacy of
aflibercept with that of ranibizumab for treating
refractory DME. This study followed a double-cross-
over design in which the treatment was switched three
times (Fig. 1). Bilateral study treatment included one
cycle of three ranibizumab injections (0.5 mg), fol-
lowed by one cycle of three aflibercept injections
(2.0 mg), a second cycle of three ranibizumab injec-
tions and a second cycle of three aflibercept injections
at 4-week intervals (±2 days).
Primary end-point was the change in mean central
foveal thickness (CFT) from baseline, and secondary
end-point was the change in mean best-corrected
visual acuity (BCVA) from baseline.
CFT was calculated from a 15-line Optopol HR
Copernicus (OPTOPOL Technology Sp., Zawiercie,
Poland) radial scan with 2812 A-scans per line. Inbuilt
Optopol software with image recognition was used to
measure CFT. CFT was defined as the distance
between the internal limiting membrane and Bruch’s
membrane. Anatomical boundaries and CFT values
were reviewed by two imaging graders (K.V. and
A.E.) to ensure that the automated algorithms accu-
rately identified the foveal location. The central foveal
location was manually redefined for only one
datapoint.
BCVAwas measured using the Snellen chart at 4 m
and was converted from the Snellen notation to the
ETDRS letter score [3].
Injection procedure
All the injections were given according to a standard-
ised procedure by a single surgeon (K.V.) in an
operating room.
Results
Unsurprisingly, after 2.5 years of ranibizumab treat-
ment, the first cycle of ranibizumab injections did not
have a significant impact on visual acuity or on
macular oedema. In contrast, the very first aflibercept
injection substantially improved the anatomical and
functional outcomes. Macular oedema reduced to
below the lowest level achieved during the previous
2.5 years of ranibizumab treatment. Reintroduction of
ranibizumab immediately worsened the anatomical
and functional status of the patient. BCVA and CFT
values reached pre-aflibercept levels by the end of the
second ranibizumab cycle. However, reintroduction of
aflibercept (second aflibercept cycle) improved the
functional and anatomical outcomes to a similar extent
as that observed with the first aflibercept cycle.




















Fig. 1 Flowchart describing the study design (one patient, both the eyes). Study injections and examinations were performed at 4-week
intervals (±2 days). wk week
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and functional outcomes for the right eye closely
followed those observed for the left eye (Table 1).
These outcomes are graphically presented as the mean
of both the eyes (Figs. 2, 3).
• Anatomical outcome Macular oedema increased
slightly during the first ranibizumab cycle (mean
CFT, ?22 lm) compared with baseline values. In
sharp contrast, macular oedema disappeared al-
most completely during the first aflibercept cycle
(Fig. 4). During the first aflibercept cycle, CFT
values were reduced by 150 lm (mean decrease in
both the eyes). CFT values at the end of the first
aflibercept cycle (mean CFT value of 251 lm in
both the eyes) were lower than the lowest levels
achieved during the previous 2.5 years of
ranibizumab treatment. Approximately, half of
the anatomical improvement (85 lm) was lost
during the second ranibizumab cycle. However,
the anatomical status improved again during the
second aflibercept cycle (mean CFT value of
228 lm in both the eyes) and exceeded the result
obtained during the first aflibercept cycle.
• Visual outcome BCVA decreased slightly during
the first ranibizumab cycle (mean BCVA, -5.1
letters) compared with baseline values. During the
first aflibercept cycle, mean BCVA increased with
17.5 letters, the first 15 letters of which were
already gained after one aflibercept injection. This
Table 1 Treatment response at the end of each treatment cycle
BCVA (letters) CFT (lm)




Both (mean) 62.7 379
Ranibizumab cycle 1
RE 50.1 -10.0 301 -4
LE 65.1 0 500 ?47
Both (mean) 57.6 -5.1 401 ?22
Aflibercept cycle 1
RE 65.1 ?15.0 233 -68
LE 85.0 ?19.9 269 -231
Both (mean) 75.1 ?17.5 251 -150
Ranibizumab cycle 2
RE 50.1 -15.0 287 ?54
LE 65.1 -19.9 384 ?115
Both (mean) 57.6 -17.5 336 ?85
Aflibercept cycle 2
RE 65.1 ?15.0 188 -99
LE 85.0 ?19.9 268 -116
Both (mean) 75.1 ?17.5 228 -108
Baseline = 4 weeks after washout from the prestudy ranibizumab treatment
Treatment cycle = 3 intravitreal injections at 4 week intervals
Treatment response = changes in BCVA and CFT values measured at 4 weeks after the last intravitreal injections of the treatment
cycle and compared with the values at the start of each cycle
BCVA Best-corrected visual acuity
EDTRS Early treatment of diabetic retinopathy study
CFT Central foveal thickness
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17.5-letter gain was completely lost during the
second ranibizumab cycle. However, the mean
BCVA increased again with 17.5 letters during the
second aflibercept cycle.
• Safety outcome Local or systemic adverse events
did not occur. In addition, blood pressure and
glycaemic values were stable throughout the study
period. Glycated haemoglobin values were mea-
sured at least once every 3 months and were
found to vary between 53.0 and 56.3 mmol/mol,
which were similar to prestudy values of
54.1–59.6 mmol/mol.
Discussion
The present double-crossover study compared the
efficacy of ranibizumab with that of aflibercept in a
patient with bilateral DME. Treatment was
prospectively switched three times and we observed
very consistent treatment differences favouring
aflibercept. The magnitude and consistency of the
benefits observed with aflibercept throughout this one-
year double-crossover study are striking and warrant
clarification. There are 3 potential explanations for the
dramatic anatomical and functional success of afliber-



















Fig. 2 Graph showing changes in mean CFT from baseline
over 48 weeks, during treatment with ranibizumab or afliber-
cept. The mean for both the eyes is shown. Note the consistent
response during the ranibizumab and aflibercept treatment
cycles. Orange squares response 4 weeks after ranibizumab,
blue triangles response 4 weeks after aflibercept, orange dots






















Fig. 3 Graph showing changes in mean BCVA (ETDRS
letters) from baseline over 48 weeks, during treatment with
ranibizumab or aflibercept. The mean for both the eyes is shown.
Note the consistent response during the ranibizumab and
aflibercept treatment cycles. Orange squares response 4 weeks
after ranibizumab, blue triangles response 4 weeks after
aflibercept, orange dots ranibizumab injections, blue dots
aflibercept injections, BCVA best-corrected visual acuity,
ETDRS Early Treatment of Diabetic Retinopathy Study
cFig. 4 Successive ocular coherence tomography (OCT) of
horizontal sections (7.0 mm) from the right and left eyes shows
the evolution of subretinal and intraretinal fluid. Central foveal
thickness (lm) is indicated for each OCT exam. Images
correspond to the OCT scans taken 4 weeks after the last (third)
injection of each treatment cycle. Baseline image was taken
after a 1-month washout period after the prestudy treatment
(near-monthly ranibizumab injections). Clear improvement is
observed during the two aflibercept treatment cycles, whereas
worsening is observed during the two ranibizumab treatment
cycles. CFT Central Foveal Thickness
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One explanation may be the superior VEGF-
binding affinity of aflibercept. Binding affinity of
aflibercept to VEGF-A is approximately 100-fold
stronger than that of ranibizumab [4]. Theoretically,
this leads to a more sustained VEGF inhibition. Still,
duration of ranibizumab action in patients with DME,
determined by measuring intraocular VEGF suppres-
sion, ranges from 27 to 42 days [5]. Because the
4-week interval between each treatment was consis-
tently adhered to, the pharmacokinetic advantage of
aflibercept unlikely explains our findings.
A second explanation may be the potential tachy-
phylaxis or tolerance to ranibizumab. Several studies
have suggested the occurrence of tachyphylaxis/tol-
erance during ranibizumab therapy [6]. Possible
mechanisms are cellular (e.g. increased fibrosis),
metabolic (e.g. increased expression of VEGF and
its receptors) or immunological (e.g. development of
neutralizing antibodies). Theoretically, there is a
difference between tachyphylaxis and tolerance:
tachyphylaxis develops quickly and can be reverted
by halting treatment temporarily, whereas tolerance
develops slowly and can be partially overcome by
increasing dosage or shortening the dosage interval
[7]. Before entering the study, the patient was treated
with near-monthly ranibizumab injections for
2.5 years. However, we do not believe that tachyphy-
laxis or tolerance explains the poor response to
ranibizumab in the present study because of the
following reasons: first, relevant to both tachyphylaxis
and tolerance, response to ranibizumab was poor but
stable throughout the 2.5-year prestudy treatment as
well as during the 1-year study period and second,
relevant to tachyphylaxis, despite the 4-month drug
holiday between the first and second ranibizumab
cycles, the response during the second ranibizumab
cycle was superposable to that during the first cycle.
A more plausible explanation might be the different
pharmacodynamic properties of the two drugs. In-
creased levels of VEGF-A [8] in patients with diabetic
retinopathy result in VEGF receptor 2-mediated break-
down of the internal blood–retinal barrier (vascular
endothelium) leading toDME [9]. In addition toVEGF-
A, PlGF-1 (Placental Growth Factor) is also implicated
in the pathogenesis of DME [10–12]. PlGF-1 induces
VEGF receptor 1-mediated rupture of the external
retinal barrier (RPE junctions), thus contributing to
diabetic retinal oedema [13]. In addition to its specific
and high-affinity binding to VEGF receptor 1, PlGF
may indirectly activate VEGF receptor 2 [14], thus
disturbing the internal retinal barrier (endothelial cells)
along with VEGF-A [15]. Patients with diabetic
retinopathy have high vitreous levels of PlGF-1 [16].
Both aflibercept and ranibizumab effectively block
vitreous VEGF-A, thereby inhibiting the activation of
VEGF receptor 2. In addition, aflibercept, but not
ranibizumab, blocks PlGF, thereby inhibiting the
binding and activation of VEGF receptors 1 and 2 [4].
Although in exudative AMD the treatment efficacy
of ranibizumab and aflibercept seems to be compara-
ble [17], there is possibly a treatment difference
between the two drugs in DME. Aetiopathogenesis of
macular oedema in diabetes is not identical to that of
exudative AMD. Although some aetiopathogenic
mechanisms of DME are similar to those of macular
oedema in exudative AMD (e.g. increased ocular
VEGF activity [9]), other mechanisms are different
(e.g. role of PlGF in DME [11]).
We have previously conducted a switch trial with
aflibercept in poor responders to ranibizumab in the
setting of exudative AMD and noted anatomical and
functional benefits after switching patients to afliber-
cept. Still, in none of the 37 eyes of that study, the extent
of the benefit of switching treatment to aflibercept came
close to the dramatic aflibercept efficacy we report here
(unpublished data from the author).
The major limitation to this study is inherent to the
nature of case studies, i.e. results are prone to inter-
individual variability of biological systems. Still, its
findings are worthwile in giving hints on differential
effects of anti-VEGF agents in different retinal
diseases and seem in line with those of the DRCR
study (protocol T), a large head-to-head study between
aflibercept and ranibizumab in patients with DME.
This study equally suggests better efficacy of afliber-
cept compared to ranibizumab, in patients with worse
levels of initial visual acuity (less than 69 EDTRS
letters) [18]. The DRCR-T study however was
conducted mainly in treatment-naı¨ve patients and
with a ranibizumab dose of 0.3 mg, a dose unique to
the United States.
In conclusion, the results of this 12-month double-
crossover case study show that aflibercept can be used
to effectively treat DME in eyes with resistance to
ranibizumab. Our findings suggest a possible benefit
of aflibercept over ranibizumab for treating DME and
highlight the role of PlGF and VEGF receptor 1 in the
aetiopathogenesis of DME.
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